{"preliminary_commentary":{"by_channel":{"x_thread":31,"youtube":7,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06551324\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"MEVPRO-1","nct_id":"NCT06551324","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mevpro-1-nct06551324. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MEVPRO-1","arms":[{"description":"Comparator Arm B: Physician's choice of enzalutamide 160 mg QD or docetaxel 75 mg/m2 intravenous (IV) every 21 days","label":"Arm B","type":"ACTIVE_COMPARATOR"},{"description":"Investigational Arm A: PF-06821497 875 mg twice daily (BID) + enzalutamide 160 mg every day (QD)","label":"Arm A","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-10-29","type":"ESTIMATED"},"conditions":["Metastatic Castrate Resistant Prostate Cancer (mCRPC)"],"enrollment":{"count":600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"PF-06821497","otherNames":["Mevrometostat"],"type":"DRUG"},{"name":"Docetaxel","otherNames":["Taxotere"],"type":"DRUG"},{"name":"Enzalutamide","otherNames":["XTANDI"],"type":"DRUG"}],"last_update":"2026-08-11","lead_sponsor":"Pfizer","official_title":"A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)","timeFrame":"Randomization up to approximately 2 years."}],"references":[{"citation":"Shore ND, Fizazi K, Schweizer MT, Castro E, Azad AA, George DJ, da Trindade KM, Zeng H, Shrivastava N, Tonkovyd S, Bock A, Nekkalapudi S, Tang Y, Lin S, Agarwal N. Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols. Future Oncol. 2026 May;22(12):1397-1408. doi: 10.1080/14796694.2026.2667441. Epub 2026 May 10.","pmid":"42108644","type":"DERIVED"}],"start_date":{"date":"2024-10-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","url":"https://clinicaltrials.gov/study/NCT06551324"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mevpro-1-nct06551324"}